Search
SOLACI Congress
HomePharmacologyOther

Other

View Category

HIGHLIGHTS

FOURIER: Efficacy of Evolocumab for Ultra-Low LDL Levels

It seems that a LDL level of 70 mg/dL is no longer low enough for high-risk secondary patients;...
solaci -
Learn More
HIGHLIGHTS

CANTOS: Anti-inflammatory Drug Canakinumab Seems to Reduce CV Events

This human monoclonal antibody that specifically targets inflammatory cells seems to reduce cardiovascular events when associated with...
solaci -
Learn More
Other

Are 7 Fr Dedicated Transradial Introducers Safe?

Courtesy of Dr. Carlos Fava. The transradial approach has been proven beneficial for quite some time now, but certain...
solaci -
Learn More
Other

When to Indicate Statin Therapy

The use of non-invasive imaging can identify or rule out subclinical atheromatosis and help reduce the number...
solaci -
Learn More
Other

Beta-Blockers for Revascularized Patients: To Prescribe or Not?

This study examines predictors and outcomes associated with the prescription of beta-blockers at discharge after a successful...
solaci -
Learn More
Acute coronary syndromes

Metoprolol before primary PCI doesn’t reduce infarction size

Original Title: Early Intravenous Beta-Blockers in Patients with ST-Segment Elevation Myocardial Infarction before Primary Percutaneous Coronary Intervention. Reference:...
solaci -
Learn More
Highlights AHA 2015

SPRINT: lower blood pressure targets for many hypertensive

Original Title: A randomized trial of intensive versus standard blood-pressure control. Presenter: Wright JR Jr. A systolic blood-pressure target...
solaci -
Learn More
Highlights AHA 2015

JUPITER Subanalysis: Reduction of LDL Determines Clinical Impact of Rosuvastatin Therapy

Original Title: Cholesterol treatment targets and clinical outcomes: a JUPITER trial update. Presenter: Paul Ridker. The lower the LDL...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

Dr. Omar Tupayachi - 0
The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Dr. Andrés Rodríguez - 0
Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Dr. Juan Manuel Pérez - 0
Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...

Institutional News

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy